Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:PLSE NASDAQ:PRCT NASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$127.12+0.2%$136.24$123.00▼$225.00$3.75B1.25558,330 shs82,214 shsPLSEPulse Biosciences$15.27+1.1%$16.20$13.50▼$25.00$1.03B1.56173,373 shs24,130 shsPRCTPROCEPT BioRobotics$57.11-2.1%$58.73$47.04▼$103.81$3.16B1.07854,201 shs230,281 shsSLNOSoleno Therapeutics$87.61+0.5%$79.81$41.50▼$90.32$4.42B-2.63853,848 shs219,177 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems0.00%-2.71%-2.93%-12.30%-11.69%PLSEPulse Biosciences0.00%-5.80%-1.31%-12.67%-5.39%PRCTPROCEPT BioRobotics0.00%+3.00%-3.11%+9.21%-13.52%SLNOSoleno Therapeutics0.00%+6.90%+9.03%+26.51%+85.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.6147 of 5 stars3.42.00.04.82.92.51.9PLSEPulse Biosciences2.7991 of 5 stars3.50.00.04.20.04.20.0PRCTPROCEPT BioRobotics2.6222 of 5 stars3.41.00.00.02.53.30.6SLNOSoleno Therapeutics4.2825 of 5 stars3.51.00.04.63.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.73Moderate Buy$210.2765.42% UpsidePLSEPulse Biosciences 3.00Buy$22.0044.12% UpsidePRCTPROCEPT BioRobotics 2.78Moderate Buy$84.1347.30% UpsideSLNOSoleno Therapeutics 3.09Buy$108.7024.07% UpsideCurrent Analyst Ratings BreakdownLatest PLSE, SLNO, INSP, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $182.007/15/2025PRCTPROCEPT BioRoboticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $68.007/11/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$105.00 ➝ $121.007/9/2025PRCTPROCEPT BioRoboticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$70.007/7/2025PRCTPROCEPT BioRoboticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform7/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.006/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M4.67$1.71 per share74.23$23.01 per share5.52PLSEPulse Biosciences$700K1,466.97N/AN/A$1.87 per share8.16PRCTPROCEPT BioRobotics$224.50M14.08N/AN/A$7.71 per share7.41SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$2.1758.5939.481.947.92%10.00%8.68%8/5/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/14/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%7/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest PLSE, SLNO, INSP, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PLSEPulse Biosciences-$0.26N/AN/AN/AN/AN/A8/7/2025Q2 2025PRCTPROCEPT BioRobotics-$0.41N/AN/AN/AN/AN/A8/6/2025Q2 2025SLNOSoleno Therapeutics-$0.85N/AN/AN/A$3.91 millionN/A8/5/2025Q2 2025INSPInspire Medical Systems$0.22N/AN/AN/A$214.50 millionN/A5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/A5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/24/2025Q1 2025PRCTPROCEPT BioRobotics-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A9.017.44PLSEPulse BiosciencesN/A15.5815.58PRCTPROCEPT BioRobotics0.138.957.75SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%PLSEPulse Biosciences76.95%PRCTPROCEPT BioRobotics89.46%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.30%PLSEPulse Biosciences71.50%PRCTPROCEPT BioRobotics17.40%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.49 million28.82 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionablePRCTPROCEPT BioRobotics43055.33 million45.70 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionablePLSE, SLNO, INSP, and PRCT HeadlinesRecent News About These CompaniesSoleno Therapeutics’ Vykat XR Exceeds Sales ExpectationsJuly 21 at 4:41 AM | msn.comBrokers Set Expectations for SLNO FY2025 EarningsJuly 20 at 2:55 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Atle Fund Management ABJuly 19 at 9:11 AM | marketbeat.com11 Best Performing Mid Cap Stocks So Far In 2025July 18 at 12:36 PM | insidermonkey.comFY2025 EPS Estimates for SLNO Raised by Cantor FitzgeraldJuly 18 at 10:31 AM | marketbeat.comBank of New York Mellon Corp Buys 234,649 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)July 18 at 3:24 AM | marketbeat.comSoleno Therapeutics: Fairly Valued Despite M&A ExpectationsJuly 16, 2025 | seekingalpha.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by TimesSquare Capital Management LLCJuly 15, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $121.00 at Robert W. BairdJuly 14, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Advisers LLC's 8th Largest PositionJuly 13, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) is Emerald Mutual Fund Advisers Trust's 7th Largest PositionJuly 12, 2025 | marketbeat.comSoleno Therapeutics Shares Dip Following $200 Million Stock Offering PricingJuly 11, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJuly 11, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume - Time to Buy?July 10, 2025 | marketbeat.comSoleno Therapeutics stock dips on proposed $200M offeringJuly 10, 2025 | msn.comSoleno Therapeutics Announces Pricing of $200 Million Public Offering of Common StockJuly 10, 2025 | globenewswire.comSoleno Therapeutics, Inc. Announces $200 Million Public Offering to Fund VYKAT XR Commercialization and R&D ActivitiesJuly 10, 2025 | quiverquant.comQSoleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XRJuly 10, 2025 | quiverquant.comQSoleno Therapeutics Announces Proposed $200 Million Public Offering of Common StockJuly 10, 2025 | globenewswire.comSoleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025July 10, 2025 | globenewswire.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 52-Week High - Time to Buy?July 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLSE, SLNO, INSP, and PRCT Company DescriptionsInspire Medical Systems NYSE:INSP$127.12 +0.29 (+0.22%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Pulse Biosciences NASDAQ:PLSE$15.26 +0.17 (+1.09%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.PROCEPT BioRobotics NASDAQ:PRCT$57.11 -1.24 (-2.12%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Soleno Therapeutics NASDAQ:SLNO$87.61 +0.41 (+0.47%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.